Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.

(MDRX)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
19.06 USD   +0.85%
11/30Sphere's TrustCommerce® Healthcare Payments Platform Now Integrated with Veradigm® Practice Management
PR
11/22Veradigm Digital Health Media Becomes the First EHR Marketing Solution to Join the Point of Care Marketing Association
BU
11/18JPMorgan Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $19, Maintains Underweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Allscripts Healthcare : 2022 Investor Day Presentation

09/28/2022 | 12:06pm EST

Investor Day

Allscripts/Veradigm

September 28, 2022

Copyright ©2022 Veradigm® | All rights reserved

1

Allscripts| Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the current beliefs and expectations of Allscripts management, only speak as of the date that they are made and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as "future," "anticipates," "believes," "estimates," "expects," "intends," "plans," "predicts," "will," "would," "could," "can," "may," "look forward," "pipeline" and similar terms. Actual results could differ significantly from those set forth in the forward-looking statements and reported results should not be considered an indication of future performance or events.

Certain factors that could cause our actual results to differ materially from those described in the forward-looking statements include, but are not limited to: our use of the proceeds from the sale of our Hospitals and Large Physician Practices Business; our ability to achieve the margin targets associated with our profitability initiatives within the contemplated time periods, if at all; the continued impact of the COVID-19 pandemic; security breaches resulting in unauthorized access to our or our clients' computer systems or data, including denial-of-services, ransomware or other Internet-based attacks; the failure by Practice Fusion to comply with the terms of the settlement agreements with the U.S. Department of Justice (the "DOJ"); the costs and burdens of compliance by Practice Fusion with the terms of its settlement agreements with the DOJ; additional investigations and proceedings from governmental entities or third parties other than the DOJ related to the same or similar conduct underlying the DOJ's investigations into Practice Fusion's business practices; our ability to recover from third parties (including insurers) any amounts paid in connection with Practice Fusion's settlement agreements with the DOJ and related inquiries; the expected financial results of businesses acquired by us; the successful integration of businesses acquired by us; the anticipated and unanticipated expenses and liabilities related to businesses acquired by us, including the civil investigation by the U.S. Attorney's Office involving our Enterprise Information Solutions business; other risks associated with investments and acquisitions; risks associated with disposition of the Hospitals and Large Physicians Practices Business, our failure to compete successfully; consolidation in our industry; current and future laws, regulations and industry initiatives; increased government involvement in our industry; the failure of markets in which we operate to develop as quickly as expected; our or our customers' failure to see the benefits of government programs; changes in interoperability or other regulatory standards; our ability to maintain and expand our business with existing clients or effectively transition clients to newer products; the effects of the realignment of our sales, services and support organizations; market acceptance of our products and services; the unpredictability of the sales and implementation cycles for our products and services; our ability to manage future growth; our ability to introduce new products and services; our ability to establish and maintain strategic relationships; risks associated with investments and acquisitions; the performance of our products; our ability to protect our intellectual property rights; the outcome of legal proceedings involving us; our ability to hire, retain and motivate key personnel; performance by our content and service providers; liability for use of content; price reductions; our ability to license and integrate third-party technologies; risks related to global operations; variability of our quarterly operating results; risks related to our outstanding indebtedness; changes in tax rates or laws; business disruptions; our ability to maintain proper and effective internal controls; and asset and long-term investment impairment charges. Additional information about these and other risks, uncertainties, and factors affecting our business is contained in our filings with the Securities and Exchange Commission, including under the caption "Risk Factors" in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Qs. We do not undertake to update forward-looking statements to reflect changed assumptions, the impact of circumstances or events that may arise after the date of the forward-looking statements, or other changes in our business, financial condition or operating results over time.

Copyright ©2022 Veradigm® | All rights reserved

2

Copyright ©2022 Veradigm® | All rights reserved

3

Agenda

Rick Poulton

Introduction

C H I E F E X E C U T I V E

O F F I C E R

Tom Langan

Veradigm Value

P R E S I D E N T & C H I E F

C O M M E R C I A L O F F I C E R

Jonathan Malek

Provider Base Foundation

S V P & G M , P R O V I D E R

Jay Bhattacharyya

Payer Connectivity

S V P & G M , P A Y E R

Stuart Green

New Perspectives for

S V P & G M , L I F E S C I E N C E

Biopharma

Leah Jones

Financial Update

C H I E F F I N A N C I A L O F F I C E R

Copyright ©2022 Veradigm® | All rights reserved

4

Our Mission

Veradigm is a healthcare technology and analytics company spanning across the

three pillars of healthcare

PAY E R P ROVI D ER B I O P HA RM A

Veradigm and the Veradigm Network are different because of our connectivity, scale, and expertise which provides

a uniquely comprehensive scope and depth of interconnected resources, so our clients can drive improved

health outcomes for the patients they serve.

Copyright ©2022 Veradigm® | All rights reserved

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Allscripts Healthcare Solutions Inc. published this content on 28 September 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 September 2022 16:05:04 UTC.


© Publicnow 2022
All news about ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
11/30Sphere's TrustCommerce® Healthcare Payments Platform Now Integrated with Veradigm® Prac..
PR
11/22Veradigm Digital Health Media Becomes the First EHR Marketing Solution to Join the Poin..
BU
11/18JPMorgan Adjusts Price Target on Allscripts Healthcare Solutions to $20 From $19, Maint..
MT
11/14Insider Sell: Allscripts Healthcare Solutions
MT
11/10Allscripts - Veradigm EHR Achieves 2015 ONC Health IT Update Certification
AQ
11/09Goldman Sachs Upgrades Allscripts Healthcare Solutions to Buy From Neutral, Adjusts Pri..
MT
11/09Veradigm EHR Achieves 2015 ONC Health IT Update Certification
BU
11/07ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. Management's Discussion and Analysis of Financia..
AQ
11/07Tranche Update on Allscripts Healthcare Solutions, Inc.'s Equity Buyback Plan announced..
CI
11/07Deutsche Bank Adjusts Allscripts Healthcare Solutions Price Target to $21 From $20, Mai..
MT
More news
Analyst Recommendations on ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
More recommendations
Financials (USD)
Sales 2022 615 M - -
Net income 2022 1,69 M - -
Net cash 2022 300 M - -
P/E ratio 2022 -318x
Yield 2022 -
Capitalization 2 082 M 2 082 M -
EV / Sales 2022 2,90x
EV / Sales 2023 2,74x
Nbr of Employees 8 000
Free-Float 38,1%
Chart ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Duration : Period :
Allscripts Healthcare Solutions, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 19,06 $
Average target price 22,00 $
Spread / Average Target 15,4%
EPS Revisions
Managers and Directors
Richard J. Poulton Chief Executive Officer & Director
Thomas Langan President
Leah Jones Vice President-Finance & Sales Support
Joseph R. Rostock Chief Technology Officer & SVP-Product Engineering
Tejal Vakharia Chief Compliance Counsel & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.3.31%2 082
VEEVA SYSTEMS INC.-31.54%27 159
PRO MEDICUS LIMITED-2.35%4 319
SECTRA AB (PUBL)-12.29%3 258
EVOLENT HEALTH, INC.3.29%2 848
OMNICELL, INC.-71.82%2 270